Epiodyne, Inc.
San Francisco, CA
- UEI
- ZB31T8V32DP6
- CAGE
- 7YZY4
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 953 Indiana St, San Francisco, CA 94107, USA
- Website
- epiodyne.com
- Founded
- 2016
- Employees
- 1-10
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Palion Therapeutics | New York, NY | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Eicosis LLC | Davis, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Nwih | Lakewood, WA | — |
| Indivior Inc. | — | 325412 Pharmaceutical Preparation Manufacturing |
| Epivario Inc. | Philadelphia, PA | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
About the company
Epiodyne, Inc., doing business as Epiodyne Inc., is a biotechnology company focused on creating small molecule opioid medicines with specifically calibrated functions to address the challenges of the Opioid Crisis. Their medicines are designed to provide pain management while minimizing addiction and respiratory depression liabilities. The company is registered as a corporate entity (not tax exempt) and has been registered in SAM.gov since 2017.
Through its federal grant awards from the National Institute on Drug Abuse within the National Institutes of Health, Epiodyne has developed opioid receptor partial agonists and antagonists aimed at providing safer alternatives for pain management, opioid overdose reversal, and treatment of opioid use disorder (OUD). The grants have funded projects involving the development of EPD2520, an oral partial mu-opioid receptor agonist demonstrating analgesic efficacy comparable to oxycodone with reduced respiratory depression and abuse potential. Additionally, Epiodyne has worked on developing potent mu-opioid receptor antagonists and low/mid-efficacy partial agonists as potential treatments for opioid overdose reversal and OUD maintenance therapy, intended to address key limitations of existing medications like naloxone, buprenorphine, and methadone.
Quick answers
Is Epiodyne, Inc. registered in SAM.gov?
Yes. Epiodyne, Inc.'s SAM.gov registration is active through October 11, 2027.
What is Epiodyne, Inc.'s most recent federal award?
Epiodyne, Inc.'s most recent federal grant award is Development of an oral analgesic with reduced liabilities (R44DA056336), from National Institute on Drug Abuse (NIH), on April 15, 2022.
On GovTribe
See Epiodyne, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors